Crit Care:ICU转出后院内死亡分析

2021-04-14 MedSci原创 MedSci原创

在ICU转出后死亡的患者中,有相当比例的患者在医院内死亡,而采用维持生命治疗的患者的死亡率更高。ICU转出后非幸存者的全身疾病严重程度评分高于幸存者。

近日,危重病医学领域权威杂志Critical Care上发表了一篇研究文章,该研究旨在明确从ICU转出的患者院内死亡的频率和危险因素。

这项大型观察性研究是一项国际性、多中心、前瞻性队列研究,招募了全球50个国家/地区的459个ICU中的重症呼吸系统患者。研究人员评估了无生命维持治疗限制的亚组人群(治疗限制)和有治疗限制的亚组人群的结局。

2186(94%)例无治疗限制的ICU患者幸存下来,而142(6%)例患者院内死亡。118名(61%)受治疗限制的患者幸存下来,而77名(39%)患者在院内死亡。ICU转出后在院内死亡的无治疗限制患者年龄较大,更有可能出现COPD,免疫功能低下或慢性肾功能衰竭,且不太可能将创伤作为ARDS的危险因素。

ICU转出后死亡的患者接受神经肌肉阻滞或采取任何辅助措施的可能性较小,并且ICU转出前的非肺SOFA评分较高。ICU转出后死亡的治疗受限患者中也观察到了类似的情形。

由此可见,在ICU转出后死亡的患者中,有相当比例的患者在医院内死亡,而采用维持生命治疗的患者的死亡率更高。ICU转出后非幸存者的全身疾病严重程度评分高于幸存者。

原始出处:

Fabiana Madotto.et al.Death in hospital following ICU discharge: insights from the LUNG SAFE study.Critical Care.2021.https://ccforum.biomedcentral.com/articles/10.1186/s13054-021-03465-0

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1635251, encodeId=ede516352518a, content=<a href='/topic/show?id=bb41983049e' target=_blank style='color:#2F92EE;'>#院内死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98304, encryptionId=bb41983049e, topicName=院内死亡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78f122436081, createdName=yuhaisheng_ibp_32061718, createdTime=Mon May 24 06:19:08 CST 2021, time=2021-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957152, encodeId=2df295e152a7, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f065480618, createdName=ms6000000306229661, createdTime=Thu Apr 15 06:36:21 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957139, encodeId=dff595e139b3, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/08ec7710e47c4f6dba6c277207bf00ec/823f09e953ea44188e56b38cd2f16334.jpg, createdBy=ec565230154, createdName=梅干儿, createdTime=Thu Apr 15 00:07:11 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957101, encodeId=67a195e101a9, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fdbc5282629, createdName=14847821m61暂无昵称, createdTime=Wed Apr 14 22:22:58 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957076, encodeId=16f995e0766c, content=有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=965c5480579, createdName=ms9000000694983282, createdTime=Wed Apr 14 21:20:06 CST 2021, time=2021-04-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1635251, encodeId=ede516352518a, content=<a href='/topic/show?id=bb41983049e' target=_blank style='color:#2F92EE;'>#院内死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98304, encryptionId=bb41983049e, topicName=院内死亡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78f122436081, createdName=yuhaisheng_ibp_32061718, createdTime=Mon May 24 06:19:08 CST 2021, time=2021-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957152, encodeId=2df295e152a7, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f065480618, createdName=ms6000000306229661, createdTime=Thu Apr 15 06:36:21 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957139, encodeId=dff595e139b3, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/08ec7710e47c4f6dba6c277207bf00ec/823f09e953ea44188e56b38cd2f16334.jpg, createdBy=ec565230154, createdName=梅干儿, createdTime=Thu Apr 15 00:07:11 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957101, encodeId=67a195e101a9, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fdbc5282629, createdName=14847821m61暂无昵称, createdTime=Wed Apr 14 22:22:58 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957076, encodeId=16f995e0766c, content=有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=965c5480579, createdName=ms9000000694983282, createdTime=Wed Apr 14 21:20:06 CST 2021, time=2021-04-14, status=1, ipAttribution=)]
    2021-04-15 ms6000000306229661

    好文章

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1635251, encodeId=ede516352518a, content=<a href='/topic/show?id=bb41983049e' target=_blank style='color:#2F92EE;'>#院内死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98304, encryptionId=bb41983049e, topicName=院内死亡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78f122436081, createdName=yuhaisheng_ibp_32061718, createdTime=Mon May 24 06:19:08 CST 2021, time=2021-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957152, encodeId=2df295e152a7, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f065480618, createdName=ms6000000306229661, createdTime=Thu Apr 15 06:36:21 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957139, encodeId=dff595e139b3, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/08ec7710e47c4f6dba6c277207bf00ec/823f09e953ea44188e56b38cd2f16334.jpg, createdBy=ec565230154, createdName=梅干儿, createdTime=Thu Apr 15 00:07:11 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957101, encodeId=67a195e101a9, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fdbc5282629, createdName=14847821m61暂无昵称, createdTime=Wed Apr 14 22:22:58 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957076, encodeId=16f995e0766c, content=有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=965c5480579, createdName=ms9000000694983282, createdTime=Wed Apr 14 21:20:06 CST 2021, time=2021-04-14, status=1, ipAttribution=)]
    2021-04-15 梅干儿

    三人行,必有我师。 #梅斯医学科研互助群# 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1635251, encodeId=ede516352518a, content=<a href='/topic/show?id=bb41983049e' target=_blank style='color:#2F92EE;'>#院内死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98304, encryptionId=bb41983049e, topicName=院内死亡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78f122436081, createdName=yuhaisheng_ibp_32061718, createdTime=Mon May 24 06:19:08 CST 2021, time=2021-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957152, encodeId=2df295e152a7, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f065480618, createdName=ms6000000306229661, createdTime=Thu Apr 15 06:36:21 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957139, encodeId=dff595e139b3, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/08ec7710e47c4f6dba6c277207bf00ec/823f09e953ea44188e56b38cd2f16334.jpg, createdBy=ec565230154, createdName=梅干儿, createdTime=Thu Apr 15 00:07:11 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957101, encodeId=67a195e101a9, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fdbc5282629, createdName=14847821m61暂无昵称, createdTime=Wed Apr 14 22:22:58 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957076, encodeId=16f995e0766c, content=有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=965c5480579, createdName=ms9000000694983282, createdTime=Wed Apr 14 21:20:06 CST 2021, time=2021-04-14, status=1, ipAttribution=)]
    2021-04-14 14847821m61暂无昵称

    好文章

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1635251, encodeId=ede516352518a, content=<a href='/topic/show?id=bb41983049e' target=_blank style='color:#2F92EE;'>#院内死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98304, encryptionId=bb41983049e, topicName=院内死亡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78f122436081, createdName=yuhaisheng_ibp_32061718, createdTime=Mon May 24 06:19:08 CST 2021, time=2021-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957152, encodeId=2df295e152a7, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f065480618, createdName=ms6000000306229661, createdTime=Thu Apr 15 06:36:21 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957139, encodeId=dff595e139b3, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/08ec7710e47c4f6dba6c277207bf00ec/823f09e953ea44188e56b38cd2f16334.jpg, createdBy=ec565230154, createdName=梅干儿, createdTime=Thu Apr 15 00:07:11 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957101, encodeId=67a195e101a9, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fdbc5282629, createdName=14847821m61暂无昵称, createdTime=Wed Apr 14 22:22:58 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957076, encodeId=16f995e0766c, content=有收获, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=965c5480579, createdName=ms9000000694983282, createdTime=Wed Apr 14 21:20:06 CST 2021, time=2021-04-14, status=1, ipAttribution=)]
    2021-04-14 ms9000000694983282

    有收获

    0

相关资讯

N Engl J Med:氧疗对ICU死亡率的影响

氧疗是目前正在重症监护病房(ICU)接受治疗的低氧性呼吸衰竭患者支持性护理的关键组成部分。然而,尽管氧气可以挽救严重低氧血症患者的生命,但过度吸氧可能是有害的。此外,在急性低氧血症患者中使用氧疗的数据

JAMA:危重患者插管不良事件发生率研究

危重病人插管后不良事件率近50%,最主要因素是心血管指标不稳定

NEJM:降低急性低氧性呼吸衰竭患者Pao2治疗目标对患者死亡风险的影响

在ICU接受治疗的急性低氧性呼吸衰竭患者,将目标动脉氧分压从90mmHg降低至60mmHg不能降低患者死亡风险。

JAMA:提高预防性抗凝治疗药物剂量对ICU新冠肺炎患者预后的影响

,接受ICU治疗的COVID-19患者中,与标准预防性抗凝治疗相比,提高依诺肝素预防性抗凝治疗剂量,在降低患者静脉或动脉血栓、体外膜氧合或30天内死亡风险方面无优势

JAMA:ICU患者有创机械通气中止及对预后的影响

各国ICU中断有创机械通气的标准各不相同,但直接拔管患者的预后最佳

胆小勿入:你们的亲人送入ICU,都会受到哪些“酷刑”

一个35岁的独肾患者,发生了肾结石、感染、感染性休克,病情危重,已经昏迷,病人老婆签字送入ICU,经过2个星期的处理后,患者重获新生,不发热了,感染指标下降了,尿量开始增多了,休克逆转了,人也清醒了,